First-in-human gene editing for lipid lowering: the initial results
Cardiovascular Research · 30.03.2024 · 120 (4) · e5-e8
DOI: 10.1093/cvr/cvae037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 30.03.2024. Verfasst von Simon Tual-Chalot und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Centre for Life, Newcastle Upon Tyne N…. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation, European Research Council, European Union's Horizon 2020.
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) is characterized by a build-up of plaque inside the arteries due to a chronic slowly evolving vascular wall inflammation and lipid accumulation that can lead to several major adverse cardiovascular events including myocardial infarction, stroke, or even death. Because the relative risk for major adverse cardiovascular events is decreased when low-density lipoprotein cholesterol (LDL-C) levels in blood are reduced,1 the European Society of Cardiology guidelines, along with other international directives, advocate the use of lipid-lowering statins therapy as a primary preventive measure for ASCVD in individuals exhibiting pathologically elevated levels of LDL-C in blood.2 However, the low adherence to statin therapies, marked by rates falling below 50% within the first year of initiation and further declining to 30% by the second year, is linked to an increased risk of mortality.2 The statin discontinuation, attributable to patient choice, lack of sufficient beneficial effect or tolerance, highlights the need for alternative therapies. PCSK9, a protease secreted by the liver, binds to the hepatocyte-derived low-density lipoprotein receptor (LDLR), preventing its recycling and enhancing its degradation. The resulting low levels of LDLR drive the increase in circulating LDL-C in ASCVD patients. The discovery of a PCSK9 inactivating mutation driving shallow cholesterol levels sparked the race to develop PCSK9 inhibitors as a novel class of medications for reducing cholesterol levels. Targeting PSCK9 by monoclonal antibodies and RNA interference (RNAi)-based therapeutic inhibitors have been the first emerging approaches. Monoclonal antibodies Evolocumab and Alirocumab are administered subcutaneously twice monthly, lower LDL-cholesterol by 60%, showed long-term safety, and successfully reduce cardiovascular endpoints.3 Inclisiran is a long-acting RNAi therapeutic agent subcutaneously injected twice yearly that neutralizes the mRNA of PCSK9 and inhibits the protein synthesis of PCSK9. In the recently reported ORION-3 extension study, Inclisiran doses were well-tolerated, and the 4-year averaged mean reduction of LDL-C was 44.2%, with reductions in PCSK9 ranging from 62.2 to 77.8%.4 A third approach consists of permanently editing PCSK9 gene using CRISPR/Cas9, a highly potent and versatile engineering tool for rapid and precise editing of DNA sequences, to produce a markedly lower exposure to LDL-C.5 Contingent upon sustained efficacy and safety, this methodology could address the challenge of sustaining long-term adherence to lifestyle modifications and pharmacological regimens. Initial in vivo murine studies using an adenoviral vector encapsulating CRISPR/Cas9 and a guide RNA targeting PCSK9 gene showed a disruption of 90% of PCSK9 expression, leading to a 40% reduction in LDL-C.5 To improve accuracy, efficiency, and safety, base editing to introduce nonsense mutations through a single adenine–thymine (A–T) to guanine–cytosine (G–C) nucleotide base pair change into PCSK9 gene, and new delivery vectors such as lipid nanoparticles (LNPs) have been developed.5 These cumulative efforts led to the engineering of VERVE-101, a CRISPR base-editing therapy composed of a mRNA encoding for an adenine base editor protein and a guide RNA targeting the PCSK9 gene, co-encapsulated within LNPs absorbed primarily by hepatocytes through a receptor-mediated process. In non-human primates, a single intravenous infusion of VERVE-101 at a dose of 1.5 mg/kg durably lowered for 2.5 years PCSK9 by 69% and LDL-C by 50%, respectively. Despite the observed dose-dependent transient elevation in alanine transaminase (ALT), consistent with other therapeutics delivered through nonclinical studies, VERVE-101 was well-tolerated, opening the investigational door to evaluate its safety and efficacy in humans (Figure 1).6 CRISPR/Cas9 in vivo gene editing for lipid-lowering therapy. Lipid nanoparticles encapsulated with a cargo comprising Cas9 mRNA encoding an adenine base editor and a PCK9-specific guide are delivered via a single intravenous administration. After infusion, apolipoprotein E opsonizes the nanoparticles, facilitating their uptake by hepatocytes via the low-density lipoprotein receptor through endocytosis and endosome formation. Following the breakdown of the lipid nanoparticle and disruption of the endosomal membrane, the active components are released into the cytoplasm. Cas9 mRNA is then translated in the cytoplasm and ultimately complexes with gRNAs to form a ribonucleoprotein. This complex enters the nucleus to induce gene editing, introducing a nonsense mutation by converting a single adenine–thymine (A–T) to guanine–cytosine (G–C) nucleotide base pair in the PCSK9 gene, thereby reducing PCSK9 gene levels. PCSK9 normally binds to the low-density lipoprotein receptor (LDLR), leading to the degradation of the receptor in the lysosomal compartment. Inhibition of the PCSK9 gene prevents further degradation of endocytosed LDLR, allowing it to be recycled back to the plasma membrane. This process results in increased clearance of LDL-C and a reduction in circulating LDL-C levels. Figure created using Biorender website. In this context, the gene editing company Verve Therapeutics presented at the American Heart Association Scientific Sessions 2023 on the 12 November 2023 the eagerly awaited interim data from Heart-1, an open-label, phase 1b clinical trial designed to evaluate the safety and tolerability of VERVE-101 in patients living with heterozygous familial hypercholesterolaemia, established ASCVD and uncontrolled hypercholesterolaemia, on maximally tolerated oral lipid-lowering therapy (eight on statin therapy; two with prior use of PCSK9-targeted therapy) (https://www.vervetx.com/sites/default/files/2023-11/Verve_AHA_2023_LBS_for%20website.pdf). This trial, the first-ever human in vivo data for base editing, included 10 participants (male: 80%, mean age: 54 years, mean LDL-C: 193 mg/dL) treated across a single intravenous infusion ascending dose study (0.1 mg/kg, n = 3; 0.3 mg/kg, n = 3; 0.45 mg/kg, n = 3, and 0.6 mg/kg, n = 1) in United-Kingdom and New Zealand centres. Study participants presented a high burden of disease at baseline, including a history of myocardial infarction and recurrent in-stent restenosis. While the two lower doses had minimal effect, in three patients receiving the higher dose, reductions in blood PCSK9 protein levels of 47, 59, and 84% were observed, while reductions in blood LDL-C of 39, 48, and 55% were reported after 180 days. This reduction in blood level LDL-C is similar to that observed after monoclonal antibodies and RNAi-based therapeutic PCSK9 inhibitors.3,4 Interestingly, the 55% LDL-C reduction, achieved with only 47% reduction in PCSK9 levels in the 0.6 mg/kg dose single participant cohort, extended up to 180 days. Nonetheless, this reduction LDL-C of 55% from a mean baseline of 193 mg/dL does not allow to reach an LDL-C target of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Centre for Life, Newcastle Upon Tyne NE1 3BZ, UK.
- Department of Cardiovascular Research, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Ludolf-Krehl-Straße 13-17, D-68167 Mannheim, Germany.
- Preventive Cardiology Clinic, Department of Cardiology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
- German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
- Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University, Ludolf-Krehl-Straße 13-17, D-68167 Mannheim, Germany.
ORCID-Profile: Konstantinos Stellos
Förderung
- British Heart Foundation
- European Research Council
- European Union's Horizon 2020
- German Research Foundation
Zitieren
APA
Tual-Chalot, S., & Stellos, K. (2024). First-in-human gene editing for lipid lowering: the initial results. Cardiovascular Research, 120(4), e5-e8. https://doi.org/10.1093/cvr/cvae037
Vancouver
Tual-Chalot S, Stellos K. First-in-human gene editing for lipid lowering: the initial results. Cardiovascular Research. 2024;120(4):e5-e8. doi:10.1093/cvr/cvae037
BibTeX
@article{TualChalot2024,
author = {Tual-Chalot, Simon and Stellos, Konstantinos},
title = {First-in-human gene editing for lipid lowering: the initial results},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {4},
pages = {e5--e8},
doi = {10.1093/cvr/cvae037}
}
EUVIMED